Highest-materiality recent filing
Estrella Immunopharma receives Nasdaq deficiency notice for failure to hold annual meeting
Received Nasdaq letter on Jan 7, 2026, citing non-compliance with Listing Rule 5620(a) for not holding annual meeting.
Estrella Immunopharma raises $8.0M in registered direct offering and private placement
Gross proceeds of $8.0M from sale of 4,063,290 shares, 1,000,000 pre-funded warrants, and 7,594,935 PIPE common warrants.
Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort
DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).
Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate
100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.
Estrella Immunopharma regains Nasdaq compliance on bid price and market value
Regained compliance with Nasdaq minimum bid price rule (5550(a)(2)) after 10 consecutive days of closing bid ≥ $1.00 (Sept 9-22, 2025).
Estrella Immunopharma appoints Jia Dengyao to Board of Directors
Board appointed Jia Dengyao as director effective September 22, 2025.
Estrella Immunopharma receives Nasdaq non-compliance notice for MVLS below $35M
Received Nasdaq notice on Aug 1, 2025 for failing to maintain minimum MVLS of $35M for 30 consecutive business days.
Estrella Immunopharma activates second clinical site for Phase I/II STARLIGHT-1 NHL trial
Baylor Research Institute in Dallas, TX now open for patient enrollment in STARLIGHT-1 trial.
Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share
Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).
Estrella Immunopharma doses first patient in STARLIGHT-1 second cohort for EB103 in NHL
First patient dosed in second cohort of Phase I/II STARLIGHT-1 trial evaluating EB103 at higher dose.
Estrella Immunopharma receives Nasdaq bid price deficiency notice; faces potential delisting
Nasdaq notified Estrella that common stock failed to maintain $1.00 minimum bid for 30 consecutive days through April 28, 2025.
Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose
First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.
Estrella Immunopharma receives Buy rating from D. Boral Capital with $16 price target
D. Boral Capital initiates coverage on Estrella (ESLA) with a Buy rating and 12-month price target of $16.00 per share.
Estrella Immunopharma regains compliance with both Nasdaq listing requirements
Regained compliance with Stockholders' Equity Requirement after market value of listed securities exceeded $35M for 10 consecutive days ending Dec 10, 2024.
Amendment extends existing up-to-$50M stock purchase agreement from Dec 30, 2024 to Dec 30, 2025.
Estrella Immunopharma changes fiscal year end to Dec 31, transition period Jul-Dec 2024
Board approved fiscal year change from June 30 to December 31 effective November 25, 2024.
Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price
Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.
Estrella Immunopharma enters consulting agreement with chairperson's company Cofame
Estrella Immunopharma entered a Consulting Agreement with Cofame Investment Management, owned by Chairperson Hong Zhang, for advisory services up to three days per week.
Estrella Immunopharma enters employment agreement with CEO Cheng Liu; base salary $250,000
Base salary of $250,000 per year, plus annual cash bonus based on performance metrics set by Compensation Committee.
Estrella Immunopharma appoints Hong Zhang as Chairperson and Board member
Hong Zhang appointed Chairperson and director effective Aug 14, 2024; board expands from 5 to 6.
Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL
First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.
Estrella Immunopharma merges wholly-owned sub Estrella Biopharma into parent
Merger effective June 30, 2024; Estrella Biopharma ceased to exist, Estrella Immunopharma survives.
Amendment No. 1 to SOW #001 for EB103 anti-CD19 ARTEMIS® clinical trial clarifies pay-on-termination obligations.
Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024
EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.
Estrella Immunopharma details $1M share repurchase: open market buys via 10b5-1 plan over 12 months
Board authorized up to $1,000,000 in common stock repurchases (first announced Jan 30, 2024).
Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial
Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.
On August 14, 2024, the Board of Directors of Estrella Immunopharma, Inc. (the “Company”) appointed Ms. Hong Zhang as Chairperson and a member of the Company’s Board of Directors (the “Board”), effective as of the same date.
Max materiality 0.85 · Median 0.55 · Most common event other_material